文献速递腹部CT

基于ΔCT影像组学特征列线图预测进展期胃癌新辅助化疗后长期疗效

Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer.
PubMed 文献 · Radiol Med · 2023-03-20

本研究纳入132例进展期胃癌患者为训练队列、45例为外部验证集,利用新辅助化疗前后CT影像组学特征变化值(delCT-RS)联合术前临床变量构建列线图(RS-CN),预测3年总生存。RS-CN在训练集C-index为0.73,预测OS的AUC为0.827,显著优于delCT-RS、ypTNM分期和TRG分级;验证集表现与训练集相当。RS-CN评分阈值177.2可区分高/低风险组,仅低风险组从辅助化疗中显著获益。

要点

  • RS-CN列线图预测进展期胃癌新辅助化疗后3年OS的AUC为0.827,优于ypTNM和TRG。
  • RS-CN评分>177.2为高风险组,≤177.2为低风险组,低风险组3年OS和DFS更优。
  • 仅低风险组患者从辅助化疗中显著获益,高风险组未见显著获益。

核心结论

  • 基于新辅助化疗前后CT影像组学特征变化值构建的列线图(RS-CN)可术前预测进展期胃癌患者3年总生存,并有助于识别最可能从辅助化疗中获益的患者。

研究设计与样本

  • 多中心队列研究:训练队列为单中心132例进展期胃癌患者,外部验证集为另一中心45例患者。
  • 基于新辅助化疗前后CT影像组学特征变化值(delCT-RS)和术前临床变量构建RS-CN列线图。
  • 采用AUC、时间依赖ROC、决策曲线分析(DCA)和C-index评估预测性能,参考标准为总生存(OS)和 disease free survival(DFS)。
  • 通过X-Tile软件确定RS-CN评分截断值177.2,将患者分为高风险组(>177.2)和低风险组(≤177.2)。

诊断标准与关键数值

  • RS-CN预测OS的C-index在训练队列为0.73。
  • 训练队列中RS-CN预测OS的AUC为0.827,显著优于delCT-RS(0.704)、ypTNM分期(0.749)和TRG分级(0.571),p<0.001。
  • RS-CN评分截断值为177.2,>177.2定义为高风险组(HRG),≤177.2定义为低风险组(LRG)。
  • LRG患者3年OS和DFS显著优于HRG患者。
  • 辅助化疗仅能显著改善LRG患者的3年OS和DFS(p<0.05)。

临床应用与阅片要点

  • 可利用新辅助化疗前后CT影像组学特征变化值联合术前临床变量(cT分期、cN分期、Lauren分型、CEA变化值)构建列线图进行术前预后分层。
  • RS-CN评分≤177.2的低风险组患者可能从辅助化疗中显著获益,>177.2的高风险组未见显著获益,可辅助临床决策。
  • RS-CN预测性能优于传统ypTNM分期和TRG分级,阅片时可关注新辅助化疗前后影像组学特征的变化。

局限性

  • 训练队列为单中心研究,外部验证集样本量较小(45例)。
  • 原文未报告影像组学特征的具体提取方法和CT扫描参数细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: No effective preoperative tool is available for predicting the prognosis of advanced gastric cancer (AGC) treated by neoadjuvant chemotherapy (NAC). We aimed to explore the association between change values ("delta") in the radiomic signatures of computed tomography (CT) (delCT-RS) before and after NAC for AGC and overall survival(OS).

METHODS AND DESIGN: A total of 132 AGC patients with AGC were studied as a training cohort in our center, and 45 patients from another center were used as an external validation set. A radiomic signatures-clinical-nomogram(RS-CN) was established using delCT-RS and preoperative clinical variables. The prediction performance of RS-CN was evaluated using the area under the receiver operating characteristic (ROC)curve (AUC values), time-dependent ROC, decision curve analysis(DCA) and C-index.

RESULTS: Multivariable Cox regression analyses showed that delCT-RS, cT-stage, cN-stage, Lauren-type and the value of variation of carcinoma embryonic antigen (CEA) between NAC were independent risk factors for 3-year OS of AGC. In the training cohort, RS-CN had a good prediction performance for OS (C-Index 0.73) and AUC values were significantly better than those of delCT-RS, ypTNM-stage and tumor regression grade(TRG) (0.827 vs 0.704 vs 0.749 vs 0.571, p < 0.001). DCA and time-dependent ROC of RS-CN were better than those of ypTNM stage, TRG grade and delCT-RS. The prediction performance of the validation set was equivalent to that of the training set. The cut-off (177.2) of RS-CN score was obtained from X-Tile software, a score of > 177.2 was defined as high-risk group(HRG), and scores of ≤ 177.2 were defined as the low-risk group(LRG). The 3-year OS and disease free survival(DFS) of patients in the LRG were significantly better than those in the HRG. Adjuvant chemotherapy(AC) can only significantly improve the 3-year OS and DFS of the LRG. (p < 0.05).

CONCLUSIONS: Our nomogram based on delCT-RS has good prediction of prognosis before surgery and helps identify patients that are most likely to benefit from AC. It works well in precise and individualised NAC in AGC.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Shen, Zheng, Ding, et al. Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer. Radiol Med. 2023. PMID: 36940007. doi:10.1007/s11547-023-01617-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。